Fig. 4. Pnx protein acts as a transcriptional repressor in cells. (A) Schematic
representation of Pnx mutants. All the Pnx mutants were constructed to be
expressed as fusion proteins with the DNA-binding domain (Gal4DB) of the yeast
transcription factor GAL4 and GFP. `Pnx' is the wild-type full-length Pnx. In
Pnx-
N the N-terminal domain of Pnx, which contains the Eh1 repressor
domain, is deleted. N-Pnx consists of only the N-terminal domain of Pnx. EnR
and VP16 are fusion proteins in which the DNA-binding domain (Gal4DB) of the
yeast transcription factor GAL4 is fused to the repressor domain of Engrailed
and the trans-activation domain (TAD) of VP16, respectively. (B) Repressor
activities of Pnx. Human 293T cells were transfected with
5xGAL4BS-luciferase and expression vectors for the Pnx variants in the
presence or absence of an expression vector for zebrafish Groucho2. Luciferase
activities were determined at 36 hours after transfection and are indicated as
fold activation/repression compared with the activity obtained from pSG424
(expressing Gal4DB alone)-transfected cells. Deletion of the N-terminal Eh1
domain abolished the repressor activity of the Pnx construct. Data points
represent the average of at least three transfections. Error bars indicate the
standard deviation of three independent experiments. The repressor activities
of the Pnx, N-Pnx and EnR constructs were enhanced up to 3.3
5.1 fold by
the co-expression of zebrafish Groucho2. Zebrafish Groucho2 alone did not
reduce the luciferase reporter activity. Error bars indicate the standard
deviation of three independent experiments. (C) The Eh1 domain of Pnx
interacts with zebrafish Groucho2. The Gal4DB-Pnx proteins and Myc
epitope-tagged Groucho2 were co-expressed in 293T cells. After 36 hours, the
Pnx proteins were immunoprecipitated with anti-GFP antibodies and
immunoblotted with anti-Myc epitope antibodies. Expression of the Pnx fusion
proteins and the Myc-tagged Groucho2 was also detected by immunoblotting the
cell lysates with anti-GFP and anti-Myc antibodies, respectively.